2. Search Result
Search Result
Results for "

parasitemia

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16779B
    Fosravuconazole L-lysine ethanolate

    BMS-379224 L-lysine ethanolate; E-1224 L-lysine ethanolate

    		 Fungal Parasite Infection
    Fosravuconazole L-lysine ethanolate (BMS-379224 L-lysine ethanolate), a proagent of Ravuconazole, is an orally active broad spectrum antifungal agent. Fosravuconazole L-lysine ethanolate can be used for candidiasis, onychomycosis and parasitemia research .
    Fosravuconazole L-lysine ethanolate
  • HY-16779
    Fosravuconazole

    BMS-379224; E-1224

    		 Fungal Parasite Infection
    Fosravuconazole (BMS-379224), a proagent of Ravuconazole, is an orally active broad spectrum antifungal agent. Fosravuconazole can be used for candidiasis, onychomycosis and parasitemia research .
    Fosravuconazole
  • HY-136448
    SJ000025081

    		Parasite Infection
    SJ000025081 is a dihydropyridine and acts as a potent antimalarial agent. SJ000025081 results in an obvious suppression of the parasitemia in a murine malaria model infected with P. yoelii .
    SJ000025081
  • HY-149938
    Antimalarial agent 25

    		Parasite Infection
    Antimalarial agent 25 is an orally active 1,4-naphthoquinones derivative with antimalarial activity. Antimalarial agent 25 shows cytotoxicity against P. falciparum. Antimalarial agent 25 inhibits P. burghei induced parasitemia in vivo .
    Antimalarial agent 25
  • HY-149939
    Antimalarial agent 26

    		Parasite Infection
    Antimalarial agent 26 is an orally active 1,4-naphthoquinones derivative with antimalarial activities. Antimalarial agent 26 shows cytotoxicity against P. falciparum and selectivity over mammalian cell lines. Antimalarial agent 26 inhibits P. burghei induced parasitemia in vivo .
    Antimalarial agent 26
  • HY-148177
    Sutidiazine

    ZY-19489; MMV 253; AZ13721412

    		 Parasite Infection
    Sutidiazine (ZY-19489) is an orally active and antimalarial agent. Sutidiazine inhibits parasitemia-induced infection. Sutidiazine shows short half-lives (approximately 7 h) and an exposure effect .
    Sutidiazine
  • HY-161384
    WJM-715

    		Parasite Infection
    WJM-715 is an antimalarial agent with an EC50 of 0.015 μM by trageting STAR-related lipid transfer protein (PfSTART1) with a KD of 14 nM .
    WJM-715
  • HY-B1896
    Piperaquine

    		Parasite Infection
    Piperaquine is a bisquinoline antimalarial agent. Piperaquine can be used in antimalarial research in combination with Artemisinin .
    Piperaquine
  • HY-147849
    JMI-105

    		Parasite Infection
    JMI-105 is a potent PfFP-2 (Plasmodium falciparum falcipain-2 protease) inhibitor. JMI-105 inhibits the growth of CQ S (3D7; IC50=8.8 µM) and CQ R (RKL-9; IC50=14.3 µM) strains of P. falciparum. JMI-105 significantly decreases parasitemia and prolonged host survival in a murine model with P. berghei ANKA infection. JMI-105 has the potential to be used as an anti-malarial agent .
    JMI-105

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: